However, a disruption in services is looming due to the Biden administration giving control of distribution over to the U.S. Department of Health and Human Services.
Florida’s supply will be cut in half Gov. Ron DeSantis announced Thursday.
The governor said he was surprised at the HHS “abrupt and sudden” announcement that it would be taking control of distribution. He said this took him by surprise because a week prior on Sept. 9 the Biden administration said they were increasing monoclonal antibody distribution by 50 percent.
Now, according to DeSantis, the HHS, as of Monday, “seized control” of the treatments. On Tuesday, DeSantis said he received “official word” that Florida’s shipments of the monoclonals would be reduced by 50 percent.
Before, providers and infusion centers, as well as the state of Florida, would simply call Amerisource, a third-party affiliate of Regeneron that makes the monoclonal antibodies treatment, and request whatever amount was needed. Now, DeSantis said this new method will make it “doubly difficult” for hospitals and other providers because they will now have to go through the state to get their treatments.
“They sprung this on us,” DeSantis said at the press conference on Thursday. “They pulled the rug out from under us.”
The new ordering process, DeSantis said, would be a disruption for in-patient services and he worries that patients will needlessly suffer. But he vowed that the state would “overcome any obstacles that HHS and the Biden administration put on them.”
“We will fight like hell to get these patients the treatment they need,” he said. “We have a responsibility to be there for them and that’s what we are going to do.”
HHS two weeks ago stealthily changed their website and began making it more difficult for states like Florida, which has used the monoclonal antibodies treatments as a way to reduce hospital admissions from COVID-19. A Texas doctor sounded the alarm that HHS was taking over the distribution of the monoclonals as was reported by The Epoch Times on Sept. 8.
“I’m very concerned about the Biden administration,” DeSantis said at Thursday’s press conference while adding that the new ordering protocol will result in a “huge disruption to services.”
Suzanne Sellman, a spokesperson for HHS, directed The Epoch Times to their website for comment.
“The recent increase in the prevalence of the Delta variant of COVID-19 has caused a substantial surge in the utilization of monoclonal antibody drugs. It remains the goal of the federal government to ensure continued availability of these drugs for current and future patients,” said an HHS statement published online Sept. 3.
“As such, HHS is immediately implementing the following changes to help promote optimal and equitable use of the available supply of monoclonal antibodies while we continue efforts to procure additional product: 1) Limiting immediate orders and shipment only to administration sites with HHSProtect accounts and current utilization reporting and 2) Reviewing all orders for alignment with utilization, currently estimated at 70% of orders.”
DeSantis said he is being proactive and has been in communication with Glaxco Smith Kline another maker of monoclonal antibodies treatment. He said he was looking into expa….